Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 28
Filter
1.
Bone Marrow Transplant ; 53(1): 64-68, 2018 01.
Article in English | MEDLINE | ID: mdl-29058696

ABSTRACT

Follistatin is an angiogenic factor elevated in the circulation after allogeneic hematopoietic cell transplantation (HCT). Elevations in follistatin plasma concentrations are associated with the onset of and poor survival after acute GvHD (aGvHD). Using data from the Blood and Marrow Transplant Clinical Trials Network 0402 study (n=247), we sought to further quantify the longitudinal associations between plasma follistatin levels in transplant recipients, as well as baseline HCT donor follistatin levels, and allogeneic HCT outcomes. Higher recipient baseline follistatin levels were predictive of development of aGvHD (P=0.04). High donor follistatin levels were also associated with the incidence of aGvHD (P<0.01). Elevated follistatin levels on day 28 were associated with the onset of grade II-IV aGvHD before day 28, higher 1-year non-relapse mortality (NRM) and lower overall survival. In multivariate analyses, individuals with follistatin levels >1088 pg/mL at day 28 had a 4-fold increased risk for NRM (relative risk (RR)=4.3, 95% confidence interval (CI) 1.9-9.9, P<0.01) and a nearly three-fold increased overall risk for mortality (RR=2.8, 95% CI 1.5-5.2, P<0.01). Given the multiple roles of follistatin in tissue inflammation and repair, and the confirmation that this biomarker is predictive of important HCT outcomes, the pathobiology of these relationships need further study.


Subject(s)
Follistatin/adverse effects , Graft vs Host Disease/etiology , Acute Disease , Adolescent , Adult , Child , Female , Graft vs Host Disease/pathology , Humans , Male , Middle Aged , Tissue Donors , Young Adult
2.
Bone Marrow Transplant ; 52(9): 1300-1303, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28581470

ABSTRACT

Epidermal growth factor (EGF) is a recently described biomarker of acute GvHD (aGvHD). Whether low plasma EGF prior to hematopoietic cell transplantation (HCT) predisposes to the development of aGvHD, or whether EGF levels fall because of severe aGvHD, is unknown. To evaluate this, we tested plasma samples collected at pre-HCT baseline, day +28 and day +100 during the course of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0402. We found that baseline EGF plasma concentrations were three-fold lower in HCT recipients compared to donors (24.3 vs 76.0 pg/mL, P<0.01). Ninety-one patients (43%) had a markedly low plasma EGF at pre-HCT baseline, defined as <2.7 pg/mL-an optimal cutpoint associated with development of grade III-IV aGvHD. Patients with these low EGF levels at pre-HCT baseline had a 2.9-fold increased risk of grade III-IV aGvHD by day +100. Patients with low EGF at day +28 after HCT had an increased risk of death (relative risk 2.3, P=0.02) by 1 year due to transplant-related toxicities, especially aGvHD. Our results suggest that very low plasma EGF early in the HCT process may predispose patients to an increased risk of death, potentially due to epithelial damage and limited repair capacity.


Subject(s)
Bone Marrow Transplantation/adverse effects , Epidermal Growth Factor/metabolism , Graft vs Host Disease/etiology , Hematopoietic Stem Cell Transplantation/methods , Transplantation Conditioning/methods , Vascularized Composite Allotransplantation/methods , Adult , Female , Humans , Male , Middle Aged
4.
Bone Marrow Transplant ; 51(12): 1556-1560, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27427920

ABSTRACT

YKL-40, also called chitinase-3-like-1 protein, is an inflammatory biomarker that has been associated with disease severity in inflammatory and malignant diseases, including AML, multiple myeloma and lymphomas. The objective of the current study was to assess the prognostic value of pretransplant recipient and donor plasma YKL-40 concentrations in patients with AML (n=624) or myelodysplastic syndrome (n=157) treated with allogeneic hematopoietic cell transplantation (HCT). In recipients, the plasma YKL-40 concentrations were increased when the HCT-comorbidity index was ⩾5 (P=0.028). There were no significant associations between plasma YKL-40 concentrations in recipients and any outcome measures. In donors with YKL-40 plasma concentrations above the age-adjusted 95th percentile, a trend toward increased grade II-IV acute GvHD in recipients was observed (adjusted hazard ratio 1.39 (95% confidence interval 1.00-1.94), P=0.050), with no significant associations with overall survival, treatment-related mortality or relapse. In conclusion, our study shows that YKL-40 does not aid risk stratification of patients undergoing allogeneic HCT, but suggests that YKL-40 may aid donor selection when multiple, otherwise equal, donors are available.


Subject(s)
Chitinase-3-Like Protein 1/blood , Donor Selection/methods , Graft vs Host Disease/blood , Hematopoietic Stem Cell Transplantation/adverse effects , Leukemia, Myeloid, Acute/therapy , Myelodysplastic Syndromes/therapy , Adolescent , Adult , Aged , Allografts , Blood Donors , Cohort Studies , Female , Growth Substances/blood , Humans , Male , Middle Aged , Prognosis , Young Adult
5.
Bone Marrow Transplant ; 51(10): 1369-1375, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27272448

ABSTRACT

Gonadal failure is a health and quality-of-life concern in hematopoietic cell transplant (HCT) survivors. While ovarian dysfunction is nearly universal following myeloablative (MA) conditioning, the risk is unclear after reduced-intensity conditioning (RIC). Gonadotropin-releasing hormone agonists decrease ovarian failure rates following conventional chemotherapy, but little is known about its effectiveness with HCT. We investigated the impact of leuprolide on ovarian function after MA conditioning and monitored ovarian function after RIC in this descriptive pilot study. Post-menarchal females <50 years undergoing HCT with adequate baseline ovarian function (follicle-stimulating hormone (FSH) level <40 mIU/mL and normal menstruation) were eligible. Prior to MA conditioning, leuprolide was administered. Those undergoing RIC were observed. FSH was measured at various time points. Seventeen women aged 12-45 years were evaluated (7 in the intervention group and 10 in the observation group). Compared to the historical high rate of ovarian failure after MA conditioning, 3 of 7 evaluable Lupron recipients had ovarian failure at a median of 703 days post transplant. Ovarian failure occurred in 1 of 10 recipients of RIC at a median follow-up of 901 days. In conclusion, leuprolide may protect ovarian function after MA conditioning. Additionally, RIC with cyclophosphamide, fludarabine and low-dose TBI has a low risk of ovarian failure.


Subject(s)
Gonadotropin-Releasing Hormone/agonists , Hematopoietic Stem Cell Transplantation/methods , Leuprolide/therapeutic use , Ovary/drug effects , Transplantation Conditioning/methods , Adolescent , Adult , Child , Female , Follicle Stimulating Hormone/blood , Gonadotropin-Releasing Hormone/therapeutic use , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Middle Aged , Myeloablative Agonists , Ovarian Function Tests , Ovary/physiology , Pilot Projects , Young Adult
6.
Bone Marrow Transplant ; 51(8): 1107-12, 2016 Aug.
Article in English | MEDLINE | ID: mdl-27064686

ABSTRACT

Donor lymphocyte infusion (DLI) is an option for relapsed hematologic malignancies or incomplete chimerism of non-malignant diseases following allogeneic hematopoietic cell transplantation (HCT). We analyzed the incidence of acute GvHD (aGvHD) in patients treated with DLI. From 1995 to 2013, 171 DLIs were given to 120 patients. The cumulative incidence of post-DLI grade II-IV aGvHD was 33% (CI 25-42%, n=40; 12 grade II), and of grade III-IV 24% (CI 16-32%, n=28). GvHD after DLI (n=46) involved the skin in 70% (n=32), lower gastrointestinal (GI) 65% (n=30), upper GI 43% (n=20) and liver 35% (n=16). Patients receiving chemotherapy accompanying the DLI (chemo-DLI) (n=37) had more frequent aGvHD and particularly lower GI GvHD. Risk factors for grade II-IV aGvHD included age >40, chemo-DLI, malignant disease and time from HCT to DLI <200 days. aGvHD response to treatment at 8 weeks was complete in 40% and complete/partial (CR/PR) in 52%. Chemo-DLI had higher response rates to aGVHD treatment in non-CML malignancies. We observed frequent, yet therapy-responsive aGvHD following DLI. GI GvHD in particular is a significant risk when giving chemotherapy prior to DLI. Improvements in DLI efficacy and GvHD management are still needed.


Subject(s)
Graft vs Host Disease/etiology , Hematologic Neoplasms/therapy , Hematopoietic Stem Cell Transplantation/adverse effects , Lymphocyte Transfusion/adverse effects , Acute Disease , Adolescent , Adult , Antineoplastic Agents/adverse effects , Female , Graft vs Host Disease/drug therapy , Hematologic Neoplasms/complications , Hematopoietic Stem Cell Transplantation/methods , Humans , Immunotherapy, Adoptive , Lymphocytes/drug effects , Male , Middle Aged , Retrospective Studies , Young Adult
7.
Leukemia ; 30(2): 456-63, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26416461

ABSTRACT

We have recently described a specialized subset of human natural killer (NK) cells with a CD56(dim)CD57(+)NKG2C(+) phenotype that expand specifically in response to cytomegalovirus (CMV) reactivation in hematopoietic cell transplant (HCT) recipients and exhibit properties characteristic of adaptive immunity. We hypothesize that these cells mediate relapse protection and improve post-HCT outcomes. In 674 allogeneic HCT recipients, we found that those who reactivated CMV had lower leukemia relapse (26% (17-35%), P=0.05) and superior disease-free survival (DFS) (55% (45-65%) P=0.04) 1 year after reduced intensity conditioning (RIC) compared with CMV seronegative recipients who experienced higher relapse rates (35% (27-43%)) and lower DFS (46% (38-54%)). This protective effect was independent of age and graft-vs-host disease and was not observed in recipients who received myeloablative regimens. Analysis of the reconstituting NK cells demonstrated that CMV reactivation is associated with both higher frequencies and greater absolute numbers of CD56(dim)CD57(+)NKG2C(+) NK cells, particularly after RIC HCT. Furthermore, expansion of these cells at 6 months posttransplant independently trended toward a lower 2-year relapse risk. Together, our data suggest that the protective effect of CMV reactivation on posttransplant relapse is in part driven by adaptive NK cell responses.


Subject(s)
CD56 Antigen/analysis , CD57 Antigens/analysis , Hematopoietic Stem Cell Transplantation , Killer Cells, Natural/immunology , Leukemia/therapy , NK Cell Lectin-Like Receptor Subfamily C/analysis , Adolescent , Adult , Cell Line, Tumor , Cytomegalovirus/physiology , Female , Humans , Leukemia/immunology , Leukemia/virology , Male , Middle Aged , Monocytes/physiology , Recurrence , Virus Activation
8.
Bone Marrow Transplant ; 49(2): 174-8, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24185590

ABSTRACT

We recently reported that adolescents and young adults (AYAs) with B-cell ALL receiving allogeneic hematopoietic cell transplantation (allo-HCT) have inferior survival compared with children, primarily because of greater TRM. We therefore hypothesized that in the setting of allo-HCT for AML, similar inferior outcomes would be observed in AYA patients as compared with children. We reviewed outcomes of 168 consecutive patients (ages 0-30 years) with AML undergoing allo-HCT at our institution. Of these, 60% (n=101) were <15 years of age and 40% (n=67) were AYAs (15-30 years of age). We identified no significant differences in 5-year overall survival (48% vs 50%, P=0.89), disease-free (47% vs 47%, P=0.89), relapse (24% vs 33%, P=0.30) or TRM (27% vs 16%, P=0.10) between the two groups. However, AYA patients had a greater incidence of grade II-IV acute (48% vs 31%, P=0.01) and chronic GVHD (22% vs 7%, P<0.01). Based on this analysis we identified no differences in survival, relapse or TRM between AYAs and children with AML receiving allo-HCT.


Subject(s)
Hematopoietic Stem Cell Transplantation/adverse effects , Leukemia, Myeloid, Acute/therapy , Transplantation Conditioning/adverse effects , Transplantation, Autologous/adverse effects , Adolescent , Adult , Child , Child, Preschool , Disease-Free Survival , Female , Humans , Infant , Infant, Newborn , Male , Treatment Outcome , Young Adult
9.
Bone Marrow Transplant ; 49(3): 440-2, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24317126

ABSTRACT

In patients with relapsed ALL, minimal residual disease (MRD) identified prior to allogeneic hematopoietic cell transplantation (HCT) is a strong predictor of relapse. We report our experience using a combination of reduced-dosing clofarabine, CY and etoposide as a 'bridge' to HCT in eight patients with high risk or relapsed ALL and pre-HCT MRD. All patients had detectable MRD (>0.01%, flow cytometry) at the start of therapy with all eight achieving MRD reduction following one cycle. The regimen was well tolerated with seven grade 3/4 toxicities occurring among four of the eight patients. Five patients (62.5%) are alive, one died from relapse (12.5%) and two from transplant-related mortality (25%). The combination of reduced-dose clofarabine, CY and etoposide as bridging therapy appears to be well tolerated in patients with relapsed ALL and is effective in reducing pre-HCT MRD.


Subject(s)
Adenine Nucleotides/administration & dosage , Arabinonucleosides/administration & dosage , Hematopoietic Stem Cell Transplantation , Neoplasm, Residual/therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Adolescent , Antimetabolites, Antineoplastic/administration & dosage , Child , Child, Preschool , Clofarabine , Cyclophosphamide/administration & dosage , Etoposide/administration & dosage , Humans , Infant , Neoplasm Recurrence, Local , Probability , Remission Induction , Time Factors , Treatment Outcome , Young Adult
10.
Bone Marrow Transplant ; 47(6): 799-803, 2012 Jun.
Article in English | MEDLINE | ID: mdl-21946383

ABSTRACT

Double umbilical cord blood transplantation (dUCBT), developed as a strategy to treat large number of patients with hematologic malignancies, frequently leads to the long-term establishment of a new hematopoietic system maintained by cells derived from a single umbilical cord blood unit. However, predicting which unit will predominate has remained elusive. This retrospective study examined the risk factor associated with unit predominance in 262 patients with hematologic malignancies who underwent dUCBT with subsequent hematopoietic recovery and complete chimerism between 2001 and 2009. Dual chimerism was detected at day 21-28, with subsequent single chimerism in 97% of the cases by day +100 and beyond. Risk factors included nucleated cell dose, CD34+ and CD3+ cell dose, colony-forming units-granulocyte macrophage dose, donor-recipient HLA match, sex and ABO match, order of infusion and cell viability. In the myeloablative setting, CD3+ cell dose was the only factor associated with unit predominance (odds ratio (OR) 4.4, 95% confidence interval (CI) 1.8-10.6; P<0.01), but in the non-myeloablative setting, CD3+ cell dose (OR 2.1, 95%CI 1.0-4.2; P=0.05) and HLA match (OR 3.4, 95%CI 1.0-11.4; P=0.05) were independent factors associated with unit predominance. Taken together, these findings suggest that immune reactivity has a role in unit predominance, and should be considered during graft selection and graft manipulation.


Subject(s)
Cord Blood Stem Cell Transplantation , Graft Survival , Hematologic Neoplasms/therapy , ABO Blood-Group System , Adolescent , Adult , Aged , Child , Child, Preschool , Female , Histocompatibility Testing , Humans , Male , Middle Aged , Retrospective Studies , Risk Factors , Transplantation Chimera , Transplantation, Homologous
11.
Bone Marrow Transplant ; 46(7): 950-5, 2011 Jul.
Article in English | MEDLINE | ID: mdl-20856210

ABSTRACT

Large registry studies have shown superior disease-free survival (DFS) with matched sibling donor (MSD) allogeneic hematopoietic cell transplantation (allo-HCT) over chemotherapy alone for patients with B-precursor acute lymphoblastic leukemia (ALL) and a late BM relapse. As most of these patients will not have an MSD, the decision to pursue an unrelated allo-HCT in second remission (CR2) or await a future relapse and perform HCT in third remission (CR3) continues to be debated. Between 1990 and 2006, 41 children with relapsed B-precursor ALL received a myeloablative allo-HCT at the University of Minnesota. Graft sources consisted of matched related donor (n=11), matched unrelated donor (n=9), and unrelated umbilical cord blood (n=21). Before allo-HCT, 15 patients had an early relapse (<36 months from diagnosis) and 26 had an initial late relapse (36 months from diagnosis). In all, 30 patients (73%) were in CR2 and 11 were in CR3 (27%) at time of allo-HCT. Five year OS/DFS were similar for patients with an early or late marrow relapse, but there was inferior DFS among late-relapse patients transplanted in CR3 compared with CR2 (30% vs 75%, P=0.04). These results suggest that allo-HCT should be pursued in children after a first marrow relapse, rather than waiting for subsequent recurrence.


Subject(s)
Hematopoietic Stem Cell Transplantation/methods , Precursor Cell Lymphoblastic Leukemia-Lymphoma/surgery , Adolescent , Bone Marrow Transplantation/methods , Child , Child, Preschool , Disease-Free Survival , Female , Humans , Male , Recurrence , Treatment Outcome , Young Adult
12.
Bone Marrow Transplant ; 46(3): 368-71, 2011 Mar.
Article in English | MEDLINE | ID: mdl-20548337

ABSTRACT

Pulmonary cytolytic thrombi (PCT) is an uncommon complication after hematopoietic cell transplantation. Although the pathogenesis is unknown, patients typically respond to systemic corticosteroid treatment. Considering corticosteroids may impair GVL reactions, we reviewed the records of 324 pediatric patients who received a transplant for leukemia and compared the outcomes of those with PCT (n=14) to those without PCT (n=310). PCT patients had a significantly more acute GVHD (aGVHD) and chronic GVHD (cGVHD). Though 3-year non-relapse mortality and OS were similar, there was significantly less relapse in patients with PCT compared to those without PCT (0 vs 28%, P=0.02), regardless of the presence or absence of aGVHD. In multivariate analysis, grade II-IV aGVHD (P=0.02), cGVHD (P=0.01) and development of PCT (P<0.01) were independently associated with less relapse. These data suggest that patients with PCT are at greater risk for GVHD, but at lower risk of leukemia relapse.


Subject(s)
Hematopoietic Stem Cell Transplantation/adverse effects , Leukemia/pathology , Leukemia/surgery , Pulmonary Embolism/etiology , Transplantation Conditioning/adverse effects , Adolescent , Child , Child, Preschool , Cord Blood Stem Cell Transplantation , Female , Graft vs Host Disease/etiology , Graft vs Host Disease/pathology , Humans , Leukemia/blood , Male , Multivariate Analysis , Pulmonary Embolism/pathology , Recurrence , Treatment Outcome
13.
Bone Marrow Transplant ; 44(3): 169-74, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19204709

ABSTRACT

Since the introduction of imatinib mesylate, the role of allogeneic hematopoietic cell transplantation (allo-HCT) for CML has essentially been reserved for patients with advanced disease or imatinib resistance. In addition, there have been concerns regarding imatinib associated cardiac toxicity. We investigated the outcome of 61 patients with CML who received a myeloablative allo-HCT at the University of Minnesota between 1999 and 2006. The median age at HCT was 38.4 (range; 6.9-56.9) years. Thirty-seven patients were in first chronic phase and twenty-four patients in a second chronic or accelerated phase at the time of HCT. Twenty-six patients received imatinib therapy before or after HCT, and thirty-five patients either never received imatinib (n=32) or received it only at the time of relapse after HCT (n=3). OS and relapse-free survival (RFS) at 2 years was 69 and 55% for the imatinib group, and 57 and 49% for the non-imatinib group (P=0.57 and 0.95, respectively). There was no difference in the risk of relapse at 2 years between the groups. Symptomatic cardiac toxicity at 1 year was reported in three imatinib group (12%) and two non-imatinib group (6%) patients (P=0.44). Thus, patients treated with imatinib either before or after myeloablative allo-HCT had no increase in cardiac toxicity.


Subject(s)
Antineoplastic Agents/adverse effects , Heart Diseases/etiology , Hematopoietic Stem Cell Transplantation/adverse effects , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy , Piperazines/adverse effects , Protein Kinase Inhibitors/adverse effects , Pyrimidines/adverse effects , Adolescent , Adult , Antineoplastic Agents/administration & dosage , Benzamides , Child , Disease-Free Survival , Female , Heart Diseases/chemically induced , Hematopoietic Stem Cell Transplantation/methods , Humans , Imatinib Mesylate , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Male , Middle Aged , Piperazines/administration & dosage , Protein Kinase Inhibitors/administration & dosage , Pyrimidines/administration & dosage , Transplantation Conditioning , Transplantation, Homologous , Treatment Outcome , Young Adult
14.
Technol Cancer Res Treat ; 8(1): 23-8, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19166239

ABSTRACT

This work reports our initial experience using multimodality image guidance to improve total marrow irradiation (TMI) using helical tomotherapy. We also monitored the details of the treatment delivery to glean information necessary for the implementation of future adaptive processes. A patient with metastatic Ewing's sarcoma underwent MRI, and bone scan imaging prior to TMI. A whole body kilovoltage CT (kVCT) scan was obtained for intensity modulated TMI treatment planning, including a boost treatment to areas of bony involvement. The delivered dose was estimated by using MVCT images from the helical tomotherapy treatment unit, compared to the expected dose distributions mapped onto the kVCT images. Clinical concerns regarding patient treatment and dosimetric uncertainties were also evaluated. A small fraction of thoracic bone volume received lower radiation dose than the prescribed dose. Reconstructed planned treatment volume (PTV) and the dose delivered to the lung were identical to planned dose. Bone scan imaging had a higher sensitivity for detecting skeletal metastasis compared to MR imaging. However the bone scan lacked sufficient specificity in three dimensions to be useful for planning conformal radiation boost treatments. Inclusion of appropriate imaging modalities improves detection of metastases, which allows the possibility of a radiation dose boost to metastases during TMI. Conformal intensity modulated radiation therapy via helical tomotherapy permitted radiation delivery to metastases in the skull with reduced dose to brain in conjunction with TMI. While TMI reduces irradiation to the lungs, onboard megavoltage computed tomography (MVCT) to verify accurate volumetric dose coverage to marrow-containing thoracic bones may be essential for successful conformal TMI treatment.


Subject(s)
Bone Marrow/radiation effects , Lung/radiation effects , Radiotherapy, Intensity-Modulated/methods , Sarcoma, Ewing/radiotherapy , Thoracic Vertebrae/radiation effects , Tomography, Spiral Computed/methods , Humans , Radiotherapy Dosage , Radiotherapy Planning, Computer-Assisted , Whole-Body Irradiation
15.
Bone Marrow Transplant ; 43(2): 107-13, 2009 Jan.
Article in English | MEDLINE | ID: mdl-18776928

ABSTRACT

The utility of imatinib in either the pre- or post-transplant period for Ph chromosome-positive (Ph+) ALL is uncertain. In addition, there have been recent concerns regarding imatinib and cardiac toxicity. We investigated the outcome of 32 patients with Ph+ ALL who received an allo-hematopoietic cell transplant (HCT) at the University of Minnesota between 1999 and 2006. The median age at HCT was 21.9 years (range: 2.8-55.2). All patients were conditioned with CY and TBI. GVHD prophylaxis was CsA based. Of the 32 patients, 15 received imatinib therapy pre- or post-HCT (imatinib group) and 17 patients received either no imatinib (n=11) or only after relapse (n=6) (non-imatinib group). Overall survival, relapse-free survival and relapse at 2 years was 61, 67 and 13% for the imatinib group as compared with 41, 35 and 35% for the non-imatinib group (P=0.19, 0.12 and 0.20, respectively). Cardiac toxicity and TRM at 2 years were similar between groups. Thus, patients treated with imatinib in either the pre- or post-transplant setting had trends toward improved outcomes and no increase in cardiac toxicity. We suggest that imatinib be included in the peri-transplant management of all patients with Ph+ ALL.


Subject(s)
Antineoplastic Agents/therapeutic use , Hematopoietic Stem Cell Transplantation , Philadelphia Chromosome , Piperazines/therapeutic use , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Pyrimidines/therapeutic use , Adolescent , Adult , Antineoplastic Agents/adverse effects , Benzamides , Child , Child, Preschool , Disease-Free Survival , Female , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Imatinib Mesylate , Male , Middle Aged , Piperazines/adverse effects , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics , Precursor Cell Lymphoblastic Leukemia-Lymphoma/surgery , Pyrimidines/adverse effects , Regression Analysis , Retrospective Studies , Young Adult
19.
Br J Cancer ; 95(9): 1274-6, 2006 Nov 06.
Article in English | MEDLINE | ID: mdl-17003777

ABSTRACT

In contrast to the positive association found in three studies between maternal anaemia during pregnancy and childhood leukaemia, no such association was found in infant leukaemia (odds ratio 0.85, 95% confidence interval 0.53-1.37).


Subject(s)
Anemia/complications , Hemoglobins/metabolism , Leukemia/etiology , Pregnancy Complications, Hematologic/blood , Adult , Anemia/blood , Case-Control Studies , Female , Humans , Infant, Newborn , Leukemia/blood , Leukemia/classification , Maternal Age , Odds Ratio , Pregnancy , Risk Factors
20.
Bone Marrow Transplant ; 37(2): 175-81, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16273111

ABSTRACT

The prognosis for many pediatric and young adult patients with solid tumors that have metastasized at the time of diagnosis or have relapsed after therapy remains very poor. The steep dose-response curve of many of these tumors to alkylating agents makes myeloablative chemotherapy followed by autologous stem cell transplantation (ASCT) an attractive potential therapy. The role of ASCT for these high-risk patients is yet to be conclusively determined. We have transplanted 36 patients on two consecutive protocols with a variety of histological diagnoses. Overall survival (OS) was 63% (95% CI: 47-79%) at 1 year and 33% (95% CI: 16-50%) at 3 years. Patients with a diagnosis of Ewing's sarcoma (ES) or desmoplastic small round cell tumor (DSRCT) had significantly better survival than those with other diagnoses with estimated 3-year OS of 54% (95% CI: 29-79%) for this group of patients (P = 0.03). There were two transplant-related deaths both attributable to hepatic veno-occlusive disease. Median follow-up among survivors is 3.5 years (range: 0.6-7.9 years). These data justify continued investigation of ASCT as a consolidation therapy in patients with metastatic or relapsed ES and DSRCT.


Subject(s)
Bone Neoplasms/mortality , Bone Neoplasms/therapy , Neoplasm Recurrence, Local/mortality , Neoplasm Recurrence, Local/therapy , Sarcoma, Ewing/mortality , Sarcoma, Ewing/therapy , Adolescent , Adult , Bone Neoplasms/complications , Bone Neoplasms/pathology , Child , Child, Preschool , Disease-Free Survival , Female , Fibroma, Desmoplastic/complications , Fibroma, Desmoplastic/mortality , Fibroma, Desmoplastic/pathology , Fibroma, Desmoplastic/therapy , Follow-Up Studies , Hepatic Veno-Occlusive Disease/etiology , Hepatic Veno-Occlusive Disease/mortality , Humans , Male , Neoplasm Recurrence, Local/complications , Neoplasm Recurrence, Local/pathology , Risk Factors , Sarcoma, Ewing/complications , Sarcoma, Ewing/pathology , Stem Cell Transplantation/methods , Stem Cell Transplantation/mortality , Survival Rate , Transplantation, Autologous
SELECTION OF CITATIONS
SEARCH DETAIL
...